Clinical Trial Update: Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating bimekizumab in psoriasis vulgaris with active psoriatic arthritis was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris
• Psoriatic Arthritis

Drugs mentioned

• Bimekizumab (bimekizumab)

Snippet

Sponsor: Innovaderm Research Inc. | Conditions: Psoriasis Vulgaris, Active Psoriatic Arthritis | Phase 4 | Status: WITHDRAWN